Published in Endocr Metab Immune Disord Drug Targets on September 01, 2008
Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J Neuroimmune Pharmacol (2010) 1.10
Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia (2011) 1.06
Cannabinoid neuroimmune modulation of SIV disease. J Neuroimmune Pharmacol (2011) 1.04
Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. Br J Pharmacol (2011) 0.89
Cannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitis. Mol Pain (2014) 0.86
Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol (2012) 0.85
Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities. Neuropathol Appl Neurobiol (2011) 0.81
CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. PLoS One (2013) 0.81
WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. J Neuroinflammation (2017) 0.76
Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C. PLoS One (2014) 0.76
Differential effects of self-reported lifetime marijuana use on interleukin-1 alpha and tumor necrosis factor in African American adults. J Behav Med (2015) 0.75
Δ9-Tetrahydrocannabinol (Δ9-THC) Promotes Neuroimmune-Modulatory MicroRNA Profile in Striatum of Simian Immunodeficiency Virus (SIV)-Infected Macaques. J Neuroimmune Pharmacol (2015) 0.75
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients. PLoS One (2017) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 8.99
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev (2003) 6.67
Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science (1985) 6.02
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
A second endogenous cannabinoid that modulates long-term potentiation. Nature (1997) 4.79
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci (1986) 4.36
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature (1994) 3.87
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol (1998) 3.45
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther (1998) 3.20
Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev (1995) 2.92
The cannabinoid system and immune modulation. J Leukoc Biol (2003) 2.87
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Functional plasticity of microglia: a review. Glia (1988) 2.76
Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem (2003) 2.75
Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) (1997) 2.55
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 2.55
Macrophages and microglia in the nervous system. Trends Neurosci (1988) 2.32
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging (1988) 2.24
Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J (1991) 2.23
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett (1998) 2.16
The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia (1993) 2.11
Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci (2003) 2.04
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci (1997) 1.99
Localization of simian immunodeficiency virus in the central nervous system of rhesus monkeys. Am J Pathol (1991) 1.93
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J (1995) 1.93
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol (2006) 1.87
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci (2006) 1.80
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem (2005) 1.78
Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol (1997) 1.71
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J (1991) 1.66
Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci (2006) 1.66
Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol (1986) 1.66
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Cognitive and motor impairments associated with SIV infection in rhesus monkeys. Science (1992) 1.60
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem (1996) 1.60
Microglia in human disease, with an emphasis on acquired immune deficiency syndrome. Lab Invest (1991) 1.60
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med (2002) 1.59
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation (2005) 1.57
Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci (2003) 1.53
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther (2000) 1.52
The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci (2001) 1.50
Tau in Alzheimer's disease. Trends Cell Biol (1998) 1.50
Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia (2005) 1.49
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol (1997) 1.49
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci (2003) 1.47
Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia (2003) 1.44
The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc (1971) 1.44
Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol (1985) 1.44
Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol (2002) 1.44
Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse (2004) 1.42
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol (2007) 1.39
Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol (1984) 1.34
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J (2000) 1.32
Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br J Pharmacol (2003) 1.31
Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol (1992) 1.31
Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur J Biochem (1996) 1.30
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia (2000) 1.30
Amoeboid and ramified microglia: their interrelationship and response to brain injury. Glia (1992) 1.29
Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol (2006) 1.26
Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest (2003) 1.26
Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol (2001) 1.25
A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci U S A (1993) 1.25
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem (2007) 1.24
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta (1996) 1.23
The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J (1998) 1.23
Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol (1998) 1.22
Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol (2005) 1.21
Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci (2007) 1.21
Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging (1997) 1.20
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett (1995) 1.20
Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur J Pharmacol (2003) 1.20
Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett (2006) 1.20
The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis (2005) 1.19
Free-living amebas: infection of the central nervous system. Mt Sinai J Med (1993) 1.19
Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol (1995) 1.18
Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience (1994) 1.18
Cannabinoid receptors and immunity. Immunol Today (1998) 1.17
Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids (2000) 1.17
Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology (1998) 1.16
In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol (2000) 1.15
A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci (2005) 1.15
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci (2003) 1.14
Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience (2006) 1.13